Products

PTRH2 antibody

Synonyms:BIT1 antibody, PTH2 antibody
Catalogue No.:FNab06951Reativity:Human, Mouse, Rat
Host:RabbitTested Application:ELISA, WB, IHC, IF
Clonality:polyclonalIsotype:IgG
  • SPECIFICATIONS
Product Name
PTRH2 antibody
Catalogue No.
FNab06951
Size
100μg
Form
liquid
Purification
Immunogen affinity purified
Purity
≥95% as determined by SDS-PAGE
Clonality
polyclonal
Isotype
IgG
Storage
PBS with 0.02% sodium azide and 50% glycerol pH 7.3, -20℃ for 12 months (Avoid repeated freeze / thaw cycles.)
Immunogen
Immunogen
peptidyl-tRNA hydrolase 2
Alternative Names
BIT1 antibody, PTH2 antibody
UniProt ID
Q9Y3E5
Observed MW
20 kDa
Application
Tested Applications
ELISA, WB, IHC, IF
Recommended dilution
WB: 1:500 - 1:2000; IHC: 1:50 - 1:200; IF: 1:10 - 1:100
Validated Images
HEK-293 cells were subjected to SDS PAGE followed by western blot with FNab06951(PTRH2 antibody) at dilution of 1:1000
Immunohistochemistry of paraffin-embedded rat brain using FNab06951(PTRH2 antibody) at dilution of 1:100
Background
The protein encoded by this gene is a mitochondrial protein with two putative domains, an N-terminal mitochondrial localization sequence, and a UPF0099 domain. In vitro assays suggest that this protein possesses peptidyl-tRNA hydrolase activity, to release the peptidyl moiety from tRNA, thereby preventing the accumulation of dissociated peptidyl-tRNA that could reduce the efficiency of translation. This protein also plays a role regulating cell survival and death. It promotes survival as part of an integrin-signaling pathway for cells attached to the extracellular matrix (ECM), but also promotes apoptosis in cells that have lost their attachment to the ECM, a process called anoikos. After loss of cell attachment to the ECM, this protein is phosphorylated, is released from the mitochondria into the cytosol, and promotes caspase-independent apoptosis through interactions with transcriptional regulators. This gene has been implicated in the development and progression of tumors, and mutations in this gene have been associated with an infantile multisystem neurologic, endocrine, and pancreatic disease (INMEPD) characterized by intellectual disability, postnatal microcephaly, progressive cerebellar atrophy, hearing impairment, polyneuropathy, failure to thrive, and organ fibrosis with exocrine pancreas insufficiency (PMID: 25574476). Alternative splicing results in multiple transcript variants encoding different isoforms.